Curriculum Vitae

Personal information

Siri Wang

Work experience

1. Employer: Norwegian Medical Products Agency
   - Start date: 102014
   - End date:
   - Position: Scientific Director
   - Activities: Norwegian PDCO delegate (2007-), Chair CMDh/EMA Paediatric Regulation Working Party (2019-2023), Expert for EDQM's PaedForm project (2017-) Paediatric related regulatory procedures, Paediatric related activities (national and international), Teaching activities Supervising PhD and MSci students
   - Country: Norway
2. Employer: Norwegian Medicines Agency
   - Start date: 072007
   - End date: 092014
   - Position: Senior Advicer
   - Activities: Norwegian PDCO delegate (2007-), Paediatric related activities (national and international), Chair of PDCO's Formulation Working Group 2008-2013, Teaching activities, Supervising PhD and MSci students
   - Country: Norway
3. Employer: Tønsberg Hospital Pharmacy, Vestfold Hospital Trust
   - Start date: 072000
   - End date: 092010
   - Position: Hospital Pharmacist
   - Activities: Contact pharmacist / ward pharmacist at the Paediatric Unit, Vestfold Hospital Trust. Clinical pharmacist at the Geriatric Unit, Vestfold Hospital Trust. Lecturer: Teaching pharmacokinetics, drug interactions, paediatric pharmacy, and general pharmacology and therapeutics to pharmacists, nurses, neonatal nurses, pharmacy students, ICU nurses. Member of EMEA Paediatric Working Party (PEG) (2005-2007)
   - Country: Norway
4. Employer: School of Pharmacy, University of Oslo
   - Start date: 1989
   - End date: 1995
   - Position: Scientific assistant / PhD student
   - Activities: Research Lecturing
   - Country: Norway
5. Employer: Haugesund Hospital Pharmacy
   - Start date: 1995
   - End date: 2000
   - Position: Hospital Pharmacist / Assistant Chief Pharmacist
   - Activities:
   - Country: Norway

Education and training

1. Subject: Dep of Pharmacology, School of Pharmacy, University of Oslo
   - Start date: 1989
   - End date: 2000
   - Qualification: PhD Pharmacy/Pharmacology
   - Organisation: Concentrations: Pharmacology / Pharmacokinetics Dissertation: Aspects of ascorbic acid kinetics: In vivo and in vitro studies with focus on methodology
   - Country: Norway
2. Subject: School of Pharmacy, University of Oslo
   - Start date: 1984
   - End date: 1990
   - Qualification: Ms Sci Pharmacy
   - Organisation: Concentration: Pharmacology
   - Country: Norway

Additional information

Publications

Karres D, Lesa G, Ligas F, Benchetrit S, Galluzzo S, Van Malderen K, Sterba J, van Dartel M, Renard M, Sisovsky P, Wang S, Norga K (2022) European regulatory strategy for supporting childhood cancer therapy developments. Eur J Cancer. 2022 Dec;177:25_29. doi: 10.1016/j.ejca.2022.09.025. Epub 2022 Oct 6

Vallet T, Bensouda Y, Saito J, Mathiesen L, Pokharkar V, Klingmann V, Peak M, Elhamdaoui O, Yamatani A, Ivanovic I, Sajith M, Münch J, Bracken L, Duncan JC, Salunke S, Wang S, Ruiz F (2021). Exploring Acceptability Drivers of Oral Antibiotics in Children: Findings from an International Observational Study. Pharmaceutics; Oct 18;13(10):1721. doi: 10.3390/pharmaceutics13101721

Lepola P, Wang S, Tötterman AM, et al. (2020) Does the EU's Paediatric Regulation work for new medicines for children in Denmark, Finland, Norway and Sweden? A cross_sectional study. BMJ Paediatrics Open; Dec 30;4(1):e000880. doi:10.1136/bmjpo_2020_000880

Staven V, Wang S, Grønlie I, Tho I (2020) Physical stability of an all_in_one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs. Eur J Hosp Pharm. Jan;27(1):36_42. doi: 10.1136/ejhpharm_2018_001562. Epub 2018 Jul 7

Norga K, Wang S. (2019) Seizing the moment – the challenge of proper timing of paediatric studies. Regulatory Rapporteur, Vol. 16, No 7/8, July/August

Blume J, Ruano AL, Wang S, Jackson DJ, Tylleskär T, Strand LI. (2018) Oral medicine acceptance in infants and toddlers: measurement properties of the caregiver_administered Children's acceptance tool (CareCAT). BMC Pediatr. Mar 22;18(1):117. doi: 10.1186/s12887_018_1080_4.

Ternik R, Liu F, Bartlett JA, Khong YM, Thiam Tan DC, Dixit T, Wang S, Galella EA, Gao Z, Klein S. (2018) Assessment of swallowability and palatability of oral dosage forms in children: Report from an M_CERSI pediatric formulation workshop. Int J Pharm. Feb 5;536(2):570_581 doi: 10.1016/j.ijpharm.2017.08.088.

Bjerknes K, Bøyum S, Kristensen S, Brustugun J, Wang S. (2017) Manipulating tablets and capsules given to hospitalised children in Norway is common practice. Acta Paediatr. Mar;106(3):503_508. doi: 10.1111/apa.13700

Staven V, Iqbal H, Wang S, Grønlie I, Tho I. (2017) Physical compatibility of total parenteral nutrition and drugs in Y_site administration to children from neonates to adolescents. J Pharm Pharmacol. Apr;69(4):448_462 doi: 10.1111/jphp.12647.

Teigen A, Wang S, Truong BT, Bjerknes K. (2016) Off_label and unlicensed medicines to hospitalised children in Norway. J Pharm Pharmacol. Jun 23. doi: 10.1111/jphp.12581.

Staven V, Wang S, Grønlie I, Tho I. (2016) Development and evaluation of a test program for Y_site compatibility testing of total parenteral nutrition and intravenous drugs. Nutr J. Mar 22;15:29

Wang S (2015) Formulations in paediatric investigation plans (PIPs): Introduction to PIP quality section and regulatory framework. Int J Pharm. Aug 15;492(1_2):332_4

Staven V, Waaseth M, Wang S, Grønlie I, Tho I (2015). Utilization of the tyndall effect for enhanced visual detection of particles in compatibility testing of intravenous fluids: validity and reliability. PDA J Pharm Sci Technol. Mar_Apr;69(2):270_83

Wang S, Huemer K_H (2014) Paediatric pharmaceutical legislation and its impact on adult and paediatric drug development: The EU regulatory view. In: D. Bar_Shalom and K. Rose (eds.), Pediatric Formulations: A Roadmap, AAPS Advances in the Pharmaceutical Sciences Series 11, American Association of Pharmaceutical Scientists 2014.

Quijano Ruiz B, Desfontaine E, Arenas_López S, Wang S (2014) Pediatric formulation issues identified in Paediatric Investigation Plans. Expert Rev Clin Pharmacol. Jan;7(1):25_30

van Riet Nales DA, Kozarewicz P, Wang S, Saint_Raymond A, Robert JL (2013) Comments on the EMA draft guideline: Final steps towards a harmonized view between regulators and industry. Int J Pharm. 457 (1): 337_339

Wang S (2012) Suitable formulations for children [Egnede legemiddelformer for barn]. Norwegian Pharmaceutical Journal [Norsk Farmaceutisk Tidsskrift] 3: 12–16 (English abstract)

van Riet_Nales DA, Wang S, Saint_Raymond A, Robert JL. (2012) The EMA quality guideline on the pharmaceutical development of medicines for paediatric use. Int J Pharm. 5;435(2):132_4

Wang S, Laitinen_Parkkonen P. (2011) Efficacy assessment in paediatric studies. Handb Exp Pharmacol. 205:149_68

Wang S, Berge GE, Sund RB. (2001) Plasma ascorbic acid concentrations in healthy dogs. Res Vet Sci 71(1): 33_5

Wang S, Hoem NO, Berge GE, Sund RB (2001) Pharmacokinetics in dogs after oral administration of two different forms of ascorbic acid. Res Vet Sci 71(1): 27_32

Wang S, Eide TC, Sogn EM, Berg KJ (1999) Plasma ascorbic acid in patients undergoing chronic haemodialysis. Eur J Clin Pharmacol 55, 527_532

Meltzer HM, Folmer M, Wang S, Lie Ø, Maage A, Mundal HH, Ydersbond TA (1997) Supplementary selenium influences the response to fatty acid induced oxidative stress in humans. Biol Trace Elem Res 60, 51_68

Mathiesen L, Wang S, Halvorsen BE, Malterud KE, Sund RB (1996) Inhibition of peroxidation in low density lipoprotein by the flavonoid myrigalon B and ascorbic acid. Biochem Pharmacol 51, 1719_1725

Christensen H, Andrew E, Berg KJ, Gedde_Dahl A, Karlsrud TS, Wang S (1995) Using problem_based learning in the pharmacotherapy teaching at the Institute of Pharmacy, University of Oslo. [Bruk av problembasert læring i farmakoterapi_undervisningen ved Farmasøytisk institutt]. Norwegian Pharmaceutical Journal [Norsk Farmaceutisk Tidsskrift]

Wang S, Schram IM, Sund RB (1995) Determination of plasma ascorbic acid by HPLC: method and stability studies. Eur J Pharm Sci 3, 231_239

Projects

Recent academic research projects:

1. Availability of new medicines for children in Nordic countries (NoMA in collaboration with Nordic agencies and FinPedMed)

2. Medicines acceptability in children _ study to increase the knowledge on which factors that affects medicines acceptability in the paediatric population in Norway, using a standardized assessment tool (University of Oslo, Norway, and ClinSearch, France)

3. Off label use of medicines in children (University of Oslo, Norway)

Regulatory project:

1. Medicines for children in the Nordic area _ closer collaboration? (project lead)

Memberships

Other Relevant Information